Welcome to systems biology and systems pharmacology at Bayer. To support a comprehensive understanding of biological systems, their interaction with pharmaceuticals and the complex dynamic processes involved, Bayer applies mechanistic modeling.
Until recently, Bayer offered software products (Computational Systems Biology Suite including PK-Sim and MoBi) and consultancy services for pharmaceutical research and development projects.
The consultancy services have been discontinued following Bayer's new setup as an integrated life sciences company.
We invite everyone in the field of Systems Pharmacology, be it in academia, industry or regulatory bodies, to use the platform. Active participation of computer and modeling & simulation scientists in the further development of the modeling & simulation platform, the incorporated systems models, processes for their qualification and application etc. is encouraged and highly welcome! Please follow the community’s activities at www.open-systems-pharmacology.org.
April 12, 2017
Two new publications regarding PBPK modeling! : A pregnancy PBPK model has been developed, and evaluated for renally cleared drugs.
March 28, 2017
Published in npj Systems Biology and Applications: Translational learning from clinical studies predicts drug pharmacokinetics across patient populations
December 19, 2016
New publications regarding PBPK modeling: Elderly, Isoniazid, DDI and Diabetes. In addition: A white paper regarding good practices in drug discovery and development